- Early data from the first EPI patients enrolled in clinical studies utilizing AzurRx’s MS1819 therapy shows positive results
- Data indicates that MS1819, a recombinant lipase derived from the yeast Yarrowia Lipolytica, is showing a favorable safety profile and encouraging signs of efficacy and drug tolerance
- The study is being performed at four sites in Australia and New Zealand
New York-based AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical company focused on the development of recombinant protein therapies for the treatment of gastrointestinal diseases and microbiome-related conditions. Patients with exocrine pancreatic insufficiency (EPI) related to chronic pancreatitis and cystic fibrosis are the focus of the company’s clinical trials now underway.
Yesterday, the company announced it has reached the 6th patient enrollment point in the ongoing 12-15 patient open-label phase IIa trial of MS1819. Results from the first six EPI patients enrolled in the study are slated to be released in September.
“We are pleased to reach this point in enrollment of this important clinical trial,” Thijs Spoor, CEO of AzurRx BioPharma, Inc., stated in a news release.
There are approximately 100,000 patients in the U.S. with EPI caused by chronic pancreatitis, according to the National Pancreas Foundation, with another estimated 30,000 patients with EPI caused by cystic fibrosis, the Cystic Fibrosis Foundation reports. When the pancreas can’t properly break down foods, poor digestion and malnutrition are the results. Patients with this condition are currently treated with porcine (derived from pig) pancreatic enzyme replacement pills.
The National Institutes of Health, analysts on Wall Street and the National Pancreas Foundation estimate the yearly market for pancreatic enzyme replacement therapy to be well over $800 million in the U.S. and at least $1.5 billion globally.
For more information, visit the company’s website at www.AzurRx.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
No comments:
Post a Comment